2021
Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection
Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.Peer-Reviewed Original ResearchConceptsSevere SARS-CoV-2 infectionSARS-CoV-2 infectionIntensive care unitComplement activationRespiratory failureEndothelial injuryCOVID-19Non-COVID cohortPersonalized clinical trialsAcute respiratory failureInvasive mechanical ventilationSevere COVID-19Tertiary care centerAlternative complement pathwayICU admissionCritical illnessCare unitMechanical ventilationRisk prognosticationWashington University SchoolWorse outcomesCare centerClinical trialsHigh riskPatients
2019
Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey
Pine A, Lee A. Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey. Blood 2019, 134: 2097. DOI: 10.1182/blood-2019-130200.Peer-Reviewed Original ResearchCancer-associated venous thromboembolismDirect oral anticoagulantsUse of DOACsLow molecular weight heparinProvider comfort levelMajority of providersHealth systemWarfarin useOral anticoagulantsClinical trialsUtilization of DOACsYale New Haven Health SystemNational Comprehensive Cancer NetworkDifferent anticoagulantsProspective real-world dataCancer-Associated ThromboembolismUse of apixabanUse of enoxaparinUse of rivaroxabanComprehensive Cancer NetworkRetrospective registry studyCancer care centerMolecular weight heparinMore providersClinical trial results
2018
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey
Pine A, Chokr N, Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. Blood 2018, 132: 1825. DOI: 10.1182/blood-2018-99-113888.Peer-Reviewed Original ResearchGene mutation profilingSouthwest Oncology GroupMyelodysplastic syndromeRisk stratificationHealth care providersMutation profilingOncology GroupMDS patientsClinical trialsCare providersWeb-based surveyConsensus evidence-based guidelinesInternational Prognostic Scoring SystemEastern Cooperative Oncology GroupGene panelAdvisory CommitteeConventional prognostic modelsThird of respondersHigh-risk patientsCooperative Oncology GroupPrognostic scoring systemRisk stratification toolManagement of patientsStem cell transplantEvidence-based guidelines
2015
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
Pine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood 2015, 126: 1138. DOI: 10.1182/blood.v126.23.1138.1138.Peer-Reviewed Original ResearchRed blood cell transfusionNon-bleeding patientsBlood cell transfusionBone marrow biopsyBlood product transfusionSouthwest Oncology GroupPlatelet transfusionsOutpatient settingAcute leukemiaPlatelet levelsCell transfusionHemoglobin levelsTransfusion practiceLumbar punctureFibrinogen levelsProduct transfusionHospitalized patientsOncology GroupClinical trialsPlatelet thresholdMost respondersConsensus evidence-based guidelinesMost providersEastern Cooperative Oncology GroupStable hospitalized patients